A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
Menopause modulates the circulating metabolome : evidence from a prospective cohort study (2022)


Karppinen, J. E., Törmäkangas, T., Kujala, U. M., Sipilä, S., Laukkanen, J., Aukee, P., Kovanen, V., & Laakkonen, E. K. (2022). Menopause modulates the circulating metabolome : evidence from a prospective cohort study. European Journal of Preventive Cardiology, 29(10), 1448-1459. https://doi.org/10.1093/eurjpc/zwac060


JYU-tekijät tai -toimittajat


Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajatKarppinen, Jari E.; Törmäkangas, Timo; Kujala, Urho M.; Sipilä, Sarianna; Laukkanen, Jari; Aukee, Pauliina; Kovanen, Vuokko; Laakkonen, Eija K.

Lehti tai sarjaEuropean Journal of Preventive Cardiology

ISSN2047-4873

eISSN2047-4881

Julkaisuvuosi2022

Ilmestymispäivä12.05.2022

Volyymi29

Lehden numero10

Artikkelin sivunumerot1448-1459

KustantajaOxford University Press (OUP)

JulkaisumaaBritannia

Julkaisun kielienglanti

DOIhttps://doi.org/10.1093/eurjpc/zwac060

Pysyvä verkko-osoitehttps://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwac060/6580397

Julkaisun avoin saatavuusAvoimesti saatavilla

Julkaisukanavan avoin saatavuusOsittain avoin julkaisukanava

Julkaisu on rinnakkaistallennettu (JYX)https://jyx.jyu.fi/handle/123456789/82724


Tiivistelmä

Aims
We studied the changes in the circulating metabolome and their relation to the menopausal hormonal shift in 17β-oestradiol and follicle-stimulating hormone levels among women transitioning from perimenopause to early postmenopause.

Methods and results
We analysed longitudinal data from 218 Finnish women, 35 of whom started menopausal hormone therapy during the study. The menopausal transition was monitored with menstrual diaries and serum hormone measurements. The median follow-up was 14 months (interquartile range: 8–20). Serum metabolites were quantified with targeted nuclear magnetic resonance metabolomics. The model results were adjusted for age, follow-up duration, education, lifestyle, and multiple comparisons. Menopause was associated with 85 metabolite measures. The concentration of apoB (0.17 standard deviation [SD], 99.5% confidence interval [CI] 0.03–0.31), very-low-density lipoprotein triglycerides (0.25 SD, CI 0.05–0.45) and particles (0.21 SD, CI 0.05–0.36), low-density lipoprotein (LDL) cholesterol (0.17 SD, CI 0.01–0.34) and particles (0.17 SD, CI 0.03–0.31), high-density lipoprotein (HDL) triglycerides (0.24 SD, CI 0.02–0.46), glycerol (0.32 SD, CI 0.07–0.58) and leucine increased (0.25 SD, CI 0.02–0.49). Citrate (−0.36 SD, CI −0.57 to −0.14) and 3-hydroxybutyrate concentrations decreased (−0.46 SD, CI −0.75 to −0.17). Most metabolite changes were associated with the menopausal hormonal shift. This explained 11% and 9% of the LDL cholesterol and particle concentration increase, respectively. Menopausal hormone therapy was associated with increased medium-to-large HDL particle count and decreased small-to-medium LDL particle and glycine concentration.

Conclusions
Menopause is associated with proatherogenic circulating metabolome alterations. Female sex hormones levels are connected to the alterations, highlighting their impact on women’s cardiovascular health.


YSO-asiasanataineenvaihduntaaineenvaihduntahäiriötaineenvaihduntatuotteetsydän- ja verisuonitaudithormonaaliset tekijätvaihdevuodethormonihoitoestradiolikohorttitutkimus

Vapaat asiasanatmenopause; hormone replacement therapy; cardiovascular diseases; metabolomics; oestradiol


Liittyvät organisaatiot


Hankkeet, joissa julkaisu on tehty


Liittyvät tutkimusaineistot


OKM-raportointiKyllä

Raportointivuosi2022

JUFO-taso1


Viimeisin päivitys 2024-03-04 klo 17:35